• Crystalys Therapeutics

  Participated · Series B · Jul 2026

  Crystalys is advancing dotinurad, a next-generation, once-daily oral URAT1 inhibitor positioned as a second-line therapy to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has regulatory approvals in Japan, China, the Philippines, Taiwan and Thailand, with supporting clinical data from those markets. The company is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY and TOPAZ trials and the Phase 2 AMETHYST study to evaluate safety and efficacy across a broad spectrum of gout patients. Crystalys aims to position dotinurad as a best-in-class option for safety and efficacy and is preparing for global commercialization. The company is headquartered in San Diego and was co-founded by Catalys Pacific and Novo Holdings. With the announced $130 million Series B, Crystalys has increased its financial runway to support late-stage development and commercial readiness.

• Odyssey Therapeutics

  Participated · Series D · Sep 2025

  Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to precisely target disease pathology in autoimmune and inflammatory diseases. Since its founding in 2021, the company has built comprehensive drug discovery and development capabilities and advanced an internally discovered program through multiple clinical milestones. Odyssey has nominated multiple development candidates and established collaborations with pharmaceutical leaders and biotech innovators. Its portfolio includes internally discovered clinical and preclinical candidates intended to induce deep and durable remission across several inflammatory diseases with unmet need. The company plans to advance these programs toward important clinical milestones and translate scientific efforts into patient benefit. Odyssey recently completed a major financing to support progression of its clinical pipeline. Odyssey Therapeutics has built a discovery and development platform that merges computational and experimental technologies to identify modality-agnostic drug targets with high clinical potential. From its Boston headquarters, the company has advanced multiple programs from ideation to a portfolio of high-value product candidates within about two years of founding in late 2021. Odyssey is focused on bringing immunology and oncology therapeutics into clinical development, with several molecules that could enter the clinic in the next 12 months. Proceeds from financing will support advancement of multiple programs into clinical studies and continued investment in discovery to build a sustainable model for therapeutic innovation. The company emphasizes a capital-efficient model and aims to deliver safe and effective precision medicines to patients with serious diseases. Leadership includes founder and CEO Gary D. Glick, Ph.D., and an experienced board guiding clinical and company-building strategy. Odyssey Therapeutics, based in Boston, raised $168M in a Series B funding round led by General Catalyst. The round included participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design, a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products, and a functional genomics platform for novel target discovery. Gary D. Glick, Ph.D. is Founder and Chief Executive Officer. Odyssey Therapeutics develops next-generation precision immunomodulators and oncology medicines using a discovery platform that combines target biology, medicinal and structural chemistry, physics-based molecular simulations, and AI/machine learning. The company was founded by Gary D. Glick, Ph.D., and is led by a team with a track record that includes helping bring more than 20 drugs to market. Odyssey intends to advance multiple pipeline programs and expand its discovery platform to broaden the druggable genome. Financially, the company completed a large Series A financing (see deal details). Odyssey is headquartered in Boston, with labs there, and is expanding its team to more than 90 scientists and staff. The company emphasizes selecting targets and therapeutic modalities aimed at maximizing clinical impact.

• Morty

  Participated · Equity · Oct 2023

  Morty builds a community‑driven discovery and review platform that helps users find and book escape rooms and haunted attractions. The company markets itself as a social copilot for friends looking for unique interactive IRL experiences. Its recommendations are powered by enthusiast communities; Morty’s escape room community is the dominant review and tracking app in that vertical. Morty drives over $500,000 in escape room bookings each month, and users have logged over 400,000 escape rooms with more than 300,000 ratings and reviews. The company recently launched a haunted‑attraction community and maintains a database of roughly 4,000 haunted attractions. Planned future verticals include immersive art/theatre, experiential food and beverage, conventions, arcades/barcades/pinball, murder mystery events, and experiential museums. The product focus is on enabling authentic, interactive real‑world experiences rather than passive consumption.

• Shoreline Biosciences

  Participated · Equity · Nov 2021

  Shoreline Biosciences is developing intelligently designed, off-the-shelf induced pluripotent stem cell (iPSC)-derived NK and macrophage cellular immunotherapies. The company focuses on standardized, targeted cell products including next-generation, more persistent iPSC-derived NK cells and macrophage-cell therapies. Shoreline is advancing proprietary iPSC differentiation methods, genetic reprogramming of disease-relevant pathways, and plans to create NK-specific CARs, switchable CAR-NK engagers, and macrophage-specific CARs. It targets both hematologic malignancies and solid tumors and has established strategic partnerships with Kite (a Gilead Company) and BeiGene. Shoreline also reports contract development and manufacturing organization (CDMO) partnerships to support manufacturing. The company is headquartered in San Diego, CA and is well-capitalized to continue pipeline advancement. Shoreline Biosciences is developing intelligently designed allogeneic, off-the-shelf natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC). The company focuses on standardized and targeted NK- and macrophage-based cell therapies for cancer and other serious diseases. It plans to use new funding to accelerate advancement of its proprietary iPSC platform and next-generation NK and macrophage cell therapy programs. Research efforts supported by the financing include work to create potent and persistent NK cell-specific chimeric antigen receptors (CARs), switchable CAR-NK cell engagers, and macrophage-specific CARs. Shoreline has entered a strategic relationship with the Advanced Cell Therapy Laboratory of UC San Diego to secure GMP manufacturing of its cell therapy products. The company was co-founded by Dan Kaufman, M.D., Ph.D., along with Steven Holtzman, William Sandborn, M.D., and Kleanthis G. Xanthopoulos, Ph.D.

• Biotheryx

  Participated · Series E · May 2021

  BioTheryX is a clinical-stage biopharmaceutical company based in San Diego focused on targeted protein degradation and multi-kinase inhibition to develop cancer treatments. Its principal platform centers on PHM "molecular glues" that harness the body's protein disposal system to selectively degrade disease-causing proteins, alongside PHM-based PROTACs and monovalent degraders. Lead programs include molecular glue BTX-1188, expected to enter the clinic by the end of 2021, and multi-kinase inhibitor BTX-A51, which is in Phase 1 with planned expansion into solid tumors and indications including acute myeloid leukemia and myelodysplastic syndromes. The company intends to use proceeds from a $92M Series E to advance multiple protein degradation programs toward IND-enabling studies and clinical development. Additional degradation programs are on track for IND-enabling activities in 2022. BioTheryX positions its platform as potentially applicable to targets previously considered undruggable and is initially focused on oncology indications with high unmet need. BioTheryX is a clinical-stage biopharmaceutical company based in San Diego focused on restoring protein homeostasis via targeted protein degradation, PHM® molecular glues, PHM®-based PROTACs and multi-kinase inhibition. Its principal technology platform is designed to use the body’s protein disposal system to selectively degrade and remove disease-causing proteins and to regulate protein equilibrium with small molecules. The company is advancing BTX-A51 in a Phase 1 clinical trial and has a pre-clinical pipeline of therapeutic candidates that leverage its PHM platforms. BioTheryX intends to use the new funding to accelerate the BTX-A51 Phase 1 timeline by adding clinical sites beyond Memorial Sloan-Kettering Cancer Center and to continue IND-enabling studies for PHM and PHM-based PROTAC candidates. The company will also use proceeds for general corporate development and to speed development of its pre-clinical programs. David Stirling, Ph.D., serves as Chairman and CEO.

No current team members are available.